124 related articles for article (PubMed ID: 35835997)
21. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD; Koll T; Gier SH; Racioppi A; White G; Lew M; Free M; Agarwal P; Bohannon LM; Johnson EJ; Selvan B; Babushok DV; Frey NV; Gill SI; Hexner EO; Martin M; Perl AE; Pratz KW; Luger SM; Chao NJ; Fisher AL; Stadtmauer EA; Porter DL; Loren AW; Bhatt VR; Gimotty PA; McCurdy SR
Transplant Cell Ther; 2024 Apr; 30(4):415.e1-415.e16. PubMed ID: 38242440
[TBL] [Abstract][Full Text] [Related]
22. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
[TBL] [Abstract][Full Text] [Related]
23. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation.
Dimitriou M; Mortera-Blanco T; Tobiasson M; Mazzi S; Lehander M; Högstrand K; Karimi M; Walldin G; Jansson M; Vonlanthen S; Ljungman P; Langemeijer S; Yoshizato T; Hellström-Lindberg E; Woll PS; Jacobsen SEW
Blood; 2024 Mar; 143(11):953-966. PubMed ID: 38096358
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with
Mizuno S; Takami A; Kawamura K; Harada K; Masayoshi M; Yano S; Ito A; Ozawa Y; Ouchi F; Ashida T; Nawa Y; Ichinohe T; Fukuda T; Atsuta Y; Yanada M
EJHaem; 2024 Apr; 5(2):369-378. PubMed ID: 38633128
[No Abstract] [Full Text] [Related]
25. Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT.
Nagler A; Labopin M; Tischer J; Raiola AM; Kunadt D; Vydra J; Blaise D; Chiusolo P; Fanin R; Winkler J; Forcade E; van Gorkom G; Ciceri F; Mohty M
Blood Adv; 2024 Apr; ():. PubMed ID: 38598754
[TBL] [Abstract][Full Text] [Related]
26. Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Olivieri DJ; Othus M; Orvain C; Rodríguez-Arbolí E; Milano F; Sandmaier BM; Khan I; Davis C; Basom RS; Appelbaum FR; Walter RB
Leukemia; 2024 Apr; 38(4):865-876. PubMed ID: 38388647
[TBL] [Abstract][Full Text] [Related]
27. Transplant in AML with measurable residual disease: proceed or defer?
Craddock C
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):528-533. PubMed ID: 36485147
[TBL] [Abstract][Full Text] [Related]
28. Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
Wang Q; Liang Z; Ren H; Dong Y; Yin Y; Wang Q; Liu W; Wang B; Han N; Li Y; Li Y
Ann Hematol; 2023 Nov; 102(11):3061-3074. PubMed ID: 37667046
[TBL] [Abstract][Full Text] [Related]
29. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation.
Nagler A; Labopin M; Canaani J; Niittyvuopio R; Socié G; Kröger N; Itäla-Remes M; Yakoub-Agha I; Labussière-Wallet H; Gallego-Hernanz MP; Deconinck E; Chevallier P; Finke J; Esteve J; Mohty M
Am J Hematol; 2020 Oct; 95(10):1135-1141. PubMed ID: 32530520
[TBL] [Abstract][Full Text] [Related]
31. Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.
Kanaan SB; Urselli F; Radich JP; Nelson JL
Blood Adv; 2023 Oct; 7(20):6066-6079. PubMed ID: 37467017
[TBL] [Abstract][Full Text] [Related]
32. Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.
Mannelli F; Piccini M; Bencini S; Gianfaldoni G; Peruzzi B; Caporale R; Scappini B; Fasano L; Quinti E; Ciolli G; Pasquini A; Crupi F; Pilerci S; Pancani F; Signori L; Tarantino D; Maccari C; Paradiso V; Annunziato F; Guglielmelli P; Vannucchi AM
Haematologica; 2024 Jan; 109(1):60-71. PubMed ID: 37345475
[TBL] [Abstract][Full Text] [Related]
33. MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study.
Cao Y; Huo W; Huang J; Yang Y; Wang Y; Chang Y; Wang L; Zhang Z; Jiang C; Hu X; Mo X
Blood Cancer J; 2024 Jan; 14(1):8. PubMed ID: 38228581
[No Abstract] [Full Text] [Related]
34. Evaluating the safety and efficacy of cryopreserved ovarian tissue transplantation in leukemia patients with different bone marrow remission status using xenotransplantation.
Li Y; Ruan X; Gu M; Du J; Jin F; Cheng J; Li Y; Jiang L; Wang Z; Yang Y; Zhang M; Mueck AO
Front Endocrinol (Lausanne); 2024; 15():1364316. PubMed ID: 38590823
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Bischof L; Ussmann J; Grimm J; Bill M; Brauer D; Backhaus D; Herrmann L; Merz M; Herling M; Metzeler KH; Franke GN; Vucinic V; Platzbecker U; Schwind S; Jentzsch M
Leukemia; 2024 Jan; 38(1):198-201. PubMed ID: 37880479
[TBL] [Abstract][Full Text] [Related]
36. Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Rodríguez-Arbolí E; Orvain C; Othus M; Walter RB
Bone Marrow Transplant; 2022 Nov; 57(11):1732-1734. PubMed ID: 36030308
[No Abstract] [Full Text] [Related]
37. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
Pasca S; Guo MZ; Wang S; Stokvis K; Shedeck A; Pallavajjala A; Shams C; Pallavajjala R; DeZern AE; Varadhan R; Gocke CD; Jones RJ; Gondek LP
Blood Adv; 2023 Aug; 7(16):4660-4670. PubMed ID: 37276081
[TBL] [Abstract][Full Text] [Related]
38. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia.
Jentzsch M; Schwind S; Bach E; Stasik S; Thiede C; Platzbecker U
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652787
[TBL] [Abstract][Full Text] [Related]
39. Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
Wienecke CP; Heida B; Venturini L; Gabdoulline R; Krüger K; Teich K; Büttner K; Wichmann M; Puppe W; Neziri B; Reuter M; Dammann E; Stadler M; Ganser A; Hambach L; Thol FR; Heuser M
Blood; 2024 Apr; ():. PubMed ID: 38669617
[TBL] [Abstract][Full Text] [Related]
40. How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL.
Muffly L; Liang EC; Dolan JG; Pulsipher MA
Blood; 2024 May; ():. PubMed ID: 38728375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
